Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.

doi:10.1200/JCO.22.00715

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Feb 2023

Grob Tim, Sanders Mathijs A, Vonk Christian M, Kavelaars Franҫois G, Rijken Melissa, Hanekamp Diana W, Gradowska Patrycja L, Cloos Jacqueline, Fløisand Yngvar, van Marwijk Kooy Marinus, Manz Markus G, Ossenkoppele Gert J, Tick Lidwine W, Havelange Violaine, Löwenberg Bob, Jongen-Lavrencic Mojca, Valk Peter J M

Abstract excerpt

PURPOSE: The applicability of FLT3-internal tandem duplications (FLT3-ITD) for assessing measurable residual disease (MRD) in acute myeloid leukemia (AML) in complete remission (CR) has been hampered by patient-specific duplications and potential instability of FLT3-ITD during relapse. Here, we comprehensively investigated the impact of next-generation sequencing (NGS)-based FLT3-ITD MRD detection on treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Neoplasm, Residual

Share to Nuclear Proteins

Share to Prognosis

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 36315929
DOI: 10.1200/JCO.22.00715
PMCID: PMC9901965

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.PMID 36315929Read ↗

<em>FLT3</em>-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for <em>FLT3</em> Inhibitor-Based TherapiesSemantic proximity Read ↗

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Semantic proximity Read ↗

Deep Sequencing of FLT3-ITD Enables Response Evaluation and Post-Treatment Monitoring in Childhood AML: An Exploratory Study.Semantic proximity Read ↗

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.Semantic proximity Read ↗

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia.Semantic proximity Read ↗

Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication.Semantic proximity Read ↗

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutationsSemantic proximity Read ↗

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.Semantic proximity Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

An NGS based MRD evaluation from acute myeloid leukemia patients.Semantic proximity Read ↗

Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.Semantic proximity Read ↗

Minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.